Clinical trial NCT05655754: Comparison of Esketamine/Propofol and Methohexital Anesthesia for ECT
Official title: A Prospective Randomized, Double Blind, Controlled, Safety and Non-inferiority Study of Esketamine Plus Propofol Compared to Methohexital Anesthesia for Electroconvulsive Therapy
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE4
Conditions: ECT
Depression
Keywords: electroconvulsive therapy
depression
esketamine
anesthesia
Lead sponsor: Medical University of Vienna
Sponsor class: OTHER
First posted: 2022-12-19
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Depressive patients, that are eligible for ECT, will be randomized to receiving either ECT with esketamine plus propofol or methohexital anesthesia for the whole series (min. 8 treatments). Participants and treating psychiatrists will be unaware or the anesthetic used; anesthetists will know the substance that it aministered during ECT. Both drugs will be compared in terms of safety, recovery time and clinical outcome.
Primary purpose: TREATMENT

Brief summary: The current anesthetic drug used as standard for ECT procedure at the Department of Psychiatry and Psychotherapy, Medical University of Vienna, is the barbiturate methohexital (Brevital®). As far as we know, methohexital is the most common anesthetic in the procedure of ECT. Only few heterogeneous randomized controlled trials to directly compare the use of (sole) ketamine and methohexital in ECT with relatively small sample sizes have been conducted so far, showing inconclusive findings: a retrospective comparison of methohexital and switch to ketamine anesthesia in 36 patients showed that ketamine prolonged seizure duration and accelerated posttreatment orientation. Others compared both drugs in terms of recovery and reorientation time showing that reorientation time was faster in the methohexital group (total N=9). Another study showed no difference in any outcome measure (depressive symptom improvement, cognition, adverse events) between both groups (total N=16, N=9 per group). Finally, a comparative investigation (total N=37, N=20 vs. N=17) detected no differences between both anesthetics but a higher systolic blood pressure posttreatment and longer motor seizure duration in the ketamine group. A favorable profile of ketamine in regards to seizure quality has been reported, however in terms of outcome measures methohexital and ketamine were similar (total N=50, N=23 vs. N=27).

The present study is designed as a prospective randomized non-inferiority trial comparing esketamine plus propofol (ratio 1:1, for better readability from now on referred to as "ketofol") to methohexital, the latter being the current standard anesthetic applied for ECT procedure at our department. Patients eligible for ECT will be randomly assigned to receive anesthesia with either ketofol or methohexital for the whole course of the individual ECT series. Group differences will be investigated both in regards to outcomes related to anesthesia, treatment-outcome and seizure quality.

Further, changes in cardiac enzyme levels before and after ECT-treatment and during the entire ECT series will be evaluated and possible group differences will be explored.

As stated above the sole/adjunct administration of ketamine as anesthetic agent for ECT has been associated with better seizure quality, similar antidepressant outcomes and anesthesia-associated events, while there is some evidence suggesting that the use of ketamine might present some advantages to other anesthetics in terms of cognitive side-effects accompanying ECT. Therefore, the aim of the present study will be to establish ketofol as a new standard for anesthesia at our Department.


Eligibility criteria: Inclusion Criteria:

* male or female inpatients
* age ≥ 18 years
* ICD-11 diagnosis of severe uni- or bipolar depression (F32.2, F32.2, F33.2, F33.3, F31.4, F31.5)
* Hamilton Depression Rating Scale HAMD17 ≥ 24
* ability to understand and willingness to sign written informed consent document
* negative urine pregnancy test in women
* anesthesiological approval for ECT (Classification of the American Society of Anesthesiologists ASA ≤ 3)
* antidepressant and antipsychotic medication in steady state for at least 7 days prior to first ECT treatment

Exclusion Criteria:

* severe somatic or neurological disease (esp. current or previous history of intracranial hypertension, uncontrolled severe hypertension, bleeds or aneurysm, recent myocardial infarction)
* current or past history of schizophrenia or schizoaffective disorder
* clinical relevant abnormalities on a general physical examination and routine laboratory screening
* pregnancy, breast feeding
* known allergy to the study drugs or compounds of the latter

Primary outcomes:
measure: antidepressant effect
timeFrame: 4 weeks
measure: recovery time
timeFrame: 4 weeks
Secondary outcomes:
measure: adverse events
timeFrame: 4 weeks
measure: concomitant medication
timeFrame: 4 weeks
measure: cognition
timeFrame: 4 weeks
measure: time to reorientation
timeFrame: 4 weeks
measure: seizure quality
timeFrame: 4 weeks
Other outcomes:
Locations:
city: Vienna
country: Austria
facility: Pia Baldinger-Melich
Study officials:
References: